Noëlle Warmenhoven

Noëlle Warmenhoven

Auto-generated profile, based on publicly available information

Noëlle Warmenhoven

Lund University, Lund Sweden

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Nature Medicine
Verified
Journal Article
Open access
SPSebastian Palmqvist
Sebastian Palmqvist
NWNoëlle Warmenhoven
Noëlle Warmenhoven
Federica AnastasiFederica Anastasi
Federica Anastasi
APAndrea Pilotto
Andrea Pilotto
SJShorena Janelidze
Shorena Janelidze
OHOskar Hansson
Oskar Hansson
Global implementation of blood tests for Alzheimer’s disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden ( n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93–0.96. In secondary care, the accuracies were 89–91%, the positive predictive values 89–95% and the negative predictive values 77–90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92–94% in secondary and primary care, excluding 12–17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations.

28 October 2024 in Brain
Verified
Journal Article
Open access
PDF file
NWNoëlle Warmenhoven
Noëlle Warmenhoven
GSGemma Salvadó
Gemma Salvadó
SJShorena Janelidze
Shorena Janelidze
NMNiklas Mattsson-Carlgren
Niklas Mattsson-Carlgren
DBDivya Bali
Divya Bali
OHOskar Hansson
Oskar Hansson
Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarker for reliable detection of Alzheimer’s disease (AD) pathology. Various p-tau217 assays have been developed, but their relative performance is unclear. We compared key plasma p-tau217 tests using cross-sectional and longitudinal measures of amyloid-β (Aβ)-PET, tau-PET, and cognition as outcomes, and benchmarked them against cerebrospinal fluid (CSF) biomarker tests. Samples from 998 individuals (mean[range] age 68.5[20.0-92.5], 53% female) from the Swedish BioFINDER-2 cohort, including both cognitively unimpaired and cognitively impaired individuals, were analyzed. Plasma p-tau217 was measured with mass spectrometry (MS) assays (the ratio between phosphorylated and non-phosphorylated [%p-tau217WashU] and p-tau217WashU) as well as with immunoassays (p-tau217Lilly, p-tau217Janssen, p-tau217ALZpath). CSF biomarkers included p-tau217Lilly, the FDA-approved p-tau181/Aβ42Elecsys, and p-tau181Elecsys. All plasma p-tau217 tests exhibited a high ability to detect abnormal Aβ-PET (AUC range: 0.91-0.96) and tau-PET (AUC range: 0.94-0.97). Plasma %p-tau217WashU had the highest performance, with significantly higher AUCs than all the immunoassays (Pdiff<0.007). For detecting Aβ-PET status, %p-tau217WashU had an accuracy of 0.93 (immunoassays: 0.83-0.88), sensitivity of 91% (immunoassays: 84-87%), and a specificity of 94% (immunoassays: 85-89%). Among immunoassays, p-tau217Lilly and plasma p-tau217ALZpath had higher AUCs than plasma p-tau217Janssen for Aβ-PET status (Pdiff<0.006), and p-tau217Lilly outperformed plasma p-tau217ALZpath for tau-PET status (Pdiff=0.025). Plasma %p-tau217WashU exhibited stronger associations with all PET load outcomes compared to immunoassays; baseline Aβ-PET load (R2: 0.72; immunoassays: 0.47-0.58; Pdiff<0.001), baseline tau-PET load (R2: 0.51; immunoassays: 0.38-0.45; Pdiff<0.001), longitudinal Aβ-PET load (R2: 0.53; immunoassays: 0.31-0.38; Pdiff<0.001) and longitudinal tau-PET load (R2: 0.50; immunoassays: 0.35-0.43; Pdiff<0.014). Among immunoassays, plasma p-tau217Lilly was more associated with Aβ-PET load than plasma p-tau217Janssen (Pdiff<0.020) and with tau-PET load than both plasma p-tau217Janssen and plasma p-tau217ALZpath (all Pdiff<0.010). Plasma %p-tau217 also correlated more strongly with baseline cognition (Mini-Mental State Examination[MMSE]) than all immunoassays (R2 %p-tau217WashU: 0.33; immunoassays: 0.27-0.30; Pdiff<0.024). The main results were replicated in an external cohort from Washington University in St Louis (n =219). Finally, p-tau217NULISA showed similar performance to other immunoassays in subsets of both cohorts. In summary, both MS- and immunoassay-based p-tau217 tests generally perform well in identifying Aβ-PET, tau-PET, and cognitive abnormalities, but %p-tau217WashU performed significantly better than all the examined immunoassays. Plasma %p-tau217 may be considered as a stand-alone confirmatory test for AD pathology, while some immunoassays might be better suited as triage tests where positive results are confirmed with a second test, which needs to be determined by future reviews incorporating results from multiple cohorts.

5 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
NWNoëlle Warmenhoven
Noëlle Warmenhoven
GSGemma Salvadó
Gemma Salvadó
SJShorena Janelidze
Shorena Janelidze
NMNiklas Mattsson-Carlgren
Niklas Mattsson-Carlgren
DBDivya Bali
Divya Bali
OHOskar Hansson
Oskar Hansson
Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarkers for reliable detection of Alzheimer’s disease (AD) pathology. Various p-tau217 assays have been developed, but their relative performance is unclear. We compared key plasma p-tau217 tests using cross-sectional and longitudinal measures of amyloid-β (Aβ)-PET, tau-PET, and cognition as outcomes, and benchmarked them against cerebrospinal fluid (CSF) biomarker tests. Samples from 998 individuals (mean[range] age 68.5[20.0-92.5], 53% female) from the Swedish BioFINDER-2 cohort were analyzed. Plasma p-tau217 was measured with mass spectrometry (MS) assays (the ratio between phosphorylated and non-phosphorylated [%p-tau217 WashU ]and p-tau217 WashU ) as well as with immunoassays (p-tau217 Lilly , p-tau217 Janssen , p-tau217 ALZpath ). CSF biomarkers included p-tau217 Lilly , and the FDA-approved p-tau181/Aβ42 Elecsys and p-tau181 Elecsys . All plasma p-tau217 tests exhibited high ability to detect abnormal Aβ-PET (AUC range: 0.91-0.96) and tau-PET (AUC range: 0.94-0.97). Plasma %p-tau217 WashU had the highest performance, with significantly higher AUCs than all the immunoassays ( P diff <0.007). For detecting Aβ-PET status, %p-tau217 WashU had an accuracy of 0.93 (immunoassays: 0.83-0.88), sensitivity of 91% (immunoassays: 84-87%), and a specificity of 94% (immunoassays: 85-89%). Among immunoassays, p-tau217 Lilly and plasma p-tau217 ALZpath had higher AUCs than plasma p-tau217 Janssen for Aβ-PET status ( P diff <0.006), and p-tau217 Lilly outperformed plasma p-tau217 ALZpath for tau-PET status ( P diff =0.025). Plasma %p-tau217 WashU exhibited higher associations with all PET load outcomes compared to immunoassays; baseline Aβ-PET load (R 2 : 0.72; immunoassays: 0.47-0.58; P diff <0.001), baseline tau-PET load (R 2 : 0.51; immunoassays: 0.38-0.45; P diff <0.001), longitudinal Aβ-PET load (R 2 : 0.53; immunoassays: 0.31-0.38; P diff <0.001) and longitudinal tau-PET load (R 2 : 0.50; immunoassays: 0.35-0.43; P diff <0.014). Among immunoassays, plasma p-tau217 Lilly was more strongly associated with Aβ-PET load than plasma p-tau217 Janssen ( P diff <0.020) and with tau-PET load than both plasma p-tau217 Janssen and plasma p-tau217 ALZpath (all P diff <0.010). Plasma %p-tau217 also correlated more strongly with baseline cognition (Mini-Mental State Examination[MMSE]) than all immunoassays (R 2 %p-tau217 WashU : 0.33; immunoassays: 0.27-0.30; P diff <0.024). The main results were replicated in an external cohort from Washington University in St Louis ( n =219). Finally, p-tau217 Nulisa showed similar performance to other immunoassays in subsets of both cohorts. In summary, both MS-and immunoassay-based p-tau217 tests generally perform well in identifying Aβ-PET, tau-PET, and cognitive abnormalities, but %p-tau217 WashU performed significantly better than all the examined immunoassays. Plasma %p-tau217 may be considered as a stand-alone confirmatory test for AD pathology, while some immunoassays might be better suited as triage tests where positive results are confirmed with a second test.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
NWNoëlle Warmenhoven
Noëlle Warmenhoven
GSGemma Salvadó
Gemma Salvadó
SJShorena Janelidze
Shorena Janelidze
NMNiklas Mattsson‐Carlgren
Niklas Mattsson‐Carlgren
HKHartmuth C. Kolb
Hartmuth C. Kolb
OHOskar Hansson
Oskar Hansson
Background: We assessed the efficacy of four plasma phospho‐tau217 (p‐tau217) biomarkers in a head‐to‐head comparison, and against two clinically available CSF biomarkers for Alzheimer’s disease (AD).Method: Samples were analyzed from 1009 individuals from the Swedish BioFINDER‐2 cohort (Table 1). We included the following biomarkers: %p‐tau217WashU, p‐tau217WashU (both mass‐spectrometry), p‐tau217Lilly, p‐tau217Janssen (both immunoassays), CSF p‐tau181 and p‐tau181/Aβ42 (Elecsys). Biomarker correlations were assessed using linear regression models. Their discriminative accuracy for global Aβ‐ and temporal meta‐ROI tau‐PET status was evaluated with receiver operating characteristic (ROC) curves. Area under the curve (AUC) values from two ROC curves were compared with DeLong tests. Linear regression models with continuous Aβ‐ and tau‐PET measures were performed. Participants were grouped into PET‐positive quartiles, which were compared with t‐tests. Effect sizes (Cohen’s D (CD)) were calculated between PET‐positive/negative groups, and between neighboring quantiles.Result: All plasma biomarkers were correlated (0.62≥Radj2≥0.92, Figure 1). %p‐tau217WashU showed the significantly largest effect size for both Aβ‐PET status and tau‐PET status (CDAβ‐PET=1.635; CDTau‐PET=1.828) compared to the other biomarkers (all pFDR <0.05). p‐tau217Janssen had a lower plasma effect size (CDAβ‐PET=1.313; CDTau‐PET=1.590), but not significantly different from p‐tau217Lilly. Although all plasma biomarkers showed high AUCs (0.90‐0.95) for Aβ‐PET positivity, %p‐tau217WashU was the highest, performing significantly better than all other biomarkers including CSF p‐tau181/Aβ42Elecsys (all pFDR<0.01) (Figure 2A). A similar pattern was observed for tau‐PET where %p‐tau217WashU also performed significantly better than all other biomarkers except for p‐tau217WashU (all pFDR<0.01) (Figure 2A). With continuous PET measures, %p‐tau217WashU showed the highest Radj2 compared to the other biomarkers for Aβ‐PET and tau‐PET (Figure 2B). In this context, all plasma ptau217 markers performed better that CSF ptau181Elecsys. Compared to CSF p‐tau181/Aβ42Elecsys, p‐tau217Lilly and p‐tau217WashU performed similarly whereas %p‐tau217WashU performed significantly better. Quantile grouping revealed that all biomarkers showed significant differences when distinguishing between negatives and early‐stage positives for both Aβ‐PET and tau‐PET, with %p‐tau217WashU consistently having the significantly largest effect size (Figure 2C). For tau‐PET, plasma biomarkers distinguished better between disease stages compared to CSF.Conclusion: When predicting Aβ‐ and tau‐PET load, both mass‐spectrometry and immunoassay methods detecting plasma p‐tau217 perform similarly to an FDA‐approved CSF test, with %p‐tau217WashU performing even better.

23 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
NWNoëlle Warmenhoven
Noëlle Warmenhoven
ABAlexa Pichet Binette
Alexa Pichet Binette
LCLyduine E. Collij
Lyduine E. Collij
SJShorena Janelidze
Shorena Janelidze
NMNiklas Mattsson‐Carlgren
Niklas Mattsson‐Carlgren
SPSebastian Palmqvist
Sebastian Palmqvist
Background: As fully automated instruments for plasma biomarkers for Alzheimer’s disease (AD) are being implemented in specialist clinics, many are questioning whether they can be used interchangeably with, or as substitutes for, gold‐standard cerebrospinal fluid (CSF) biomarkers. We aimed to compare fully automated Lumipulse plasma assays that are under FDA evaluation with FDA‐approved CSF assays. Method: We included patients with subjective cognitive decline, mild cognitive impairment, and dementia from the BioFINDER‐Memory Clinic ( n =122), BioFINDER‐Primary Care ( n =169) and ADNI ( n =165) cohorts, in which plasma p ‐tau217 and plasma Aβ42 were measured with Lumipulse assays (Table 1). Plasma biomarkers were compared with CSF Aβ42/Aβ40 (Lumipulse) in the BioFINDER cohorts and CSF p ‐tau181/Aβ42 (Elecsys) in ADNI. Previously published one‐ and two‐cutoff approaches were used for the biomarkers. The two‐cutoff approach applies upper (positivity) and lower (negativity) cutoffs with intermediate cases being those with results in between the cutoffs (excluded in the analyses). The outcome was presence of AD pathology (visual read Aβ‐PET). Result: Plasma p ‐tau217 identified AD pathology with AUCs of 0.95 (memory clinic), 0.89 (primary care) and 0.94 (ADNI). For p ‐tau217/Aβ42, AUCs of 0.95 (memory clinic), 0.90 (primary care), and 0.92 (ADNI) were observed (Figure 1B,E,H). CSF performed similar in BioFINDER (AUCs 0.91–0.92; all p >0.304) and better in ADNI (AUC 0.98, p =0.032). When applying one cutoff, plasma p ‐tau217 and p ‐tau217/Aβ42 had higher accuracies than CSF Aβ42/Aβ40 in BioFINDER‐Memory Clinic (80‐91%, all p 0.488, Figure 1D) and ADNI (88‐92%, all p >0.152, Figure 1G). With two cutoffs, no significant differences between plasma p ‐tau217 (92%) or plasma p ‐tau217/Aβ42 (91%) and CSF biomarkers (89‐93%) were observed in BioFINDER‐Memory Clinic or ADNI (Figure 2A,G). In primary care, plasma p ‐tau217 (86%), but not p ‐tau217/Aβ42 (90%), had lower accuracy than CSF Aβ42/Aβ40 (92%, p =0.028; Figure 2E). Conclusion: Plasma p ‐tau217 and p ‐tau217/Aβ42 Lumipulse demonstrated similar or slightly inferior performance compared with FDA‐approved CSF tests for detecting AD pathology across three cohorts, including primary care. Since these plasma assays are under FDA‐review for AD diagnosis, the results are essential for validating their performance relative to CSF biomarkers. Additional comparisons will be presented at AAIC.